Study wrapper · #1383
A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy.
Editor's note
The gap between investigator-reported malnutrition (0.12%) and objective laboratory flags (2.9% vs 1.77% on placebo) is the notable finding, suggesting standard adverse-event reporting understates nutritional risk on high-potency incretins. Trial populations and endpoints vary across the SURMOUNT, STEP, SCALE, and OASIS programs, so pooled deficits are estimates, and the proposed monitoring algorithm is the authors' construct, not a tested protocol. Most relevant to older adults and anyone sustaining large deficits without attention to protein intake and resistance training.
Plain-language abstract
Pooling 19 randomized trials of semaglutide, tirzepatide, and liraglutide, this meta-analysis found daily energy-intake drops of 24-39%, measurable fat-free-mass loss on high-dose tirzepatide, and laboratory signs of nutritional strain (low lymphocyte counts) at nearly double the placebo rate — even though formally reported malnutrition was rare.